AOD-9604 corresponds to the C-terminal fragment of human growth hormone and was developed to separate the lipolytic activity of the hormone from its growth-promoting effects.
Key Takeaways
- The C-terminal region of growth hormone was associated with lipid metabolism in older work, so the fragment was developed to reproduce that activity without triggering the receptor-mediated growth effects of the full hormone.
- Human trials exploring weight loss did not demonstrate clinically meaningful efficacy, and development was discontinued.
- When assessing any peptide fragment, ask whether the parent hormone’s effect was actually reproduced in humans rather than in rodents.
Rationale for the fragment
The C-terminal region of growth hormone was associated with lipid metabolism in older work, so the fragment was developed to reproduce that activity without triggering the receptor-mediated growth effects of the full hormone. The design logic is straightforward even if the outcome was not.
Preclinical metabolic findings
Rodent studies reported changes in lipolysis and fat mass. The magnitude of these effects varied with diet and strain, and the peptide did not show the receptor-mediated effects associated with intact growth hormone, which was the intended result.
For related mechanism work, see thymosin alpha-1.
Clinical development outcome
Human trials exploring weight loss did not demonstrate clinically meaningful efficacy, and development was discontinued. This is one of the clearer examples in the peptide field of a sound mechanistic rationale failing at the clinical stage.
Why it still circulates
The compound continues to appear in research catalogues and in consumer discussions long after development stopped. It is a useful case study in why mechanistic plausibility and clinical benefit are different standards.
Lessons for reviewers
When assessing any peptide fragment, ask whether the parent hormone’s effect was actually reproduced in humans rather than in rodents. Fragment stories are particularly prone to stopping at the preclinical stage.
Experimental Conditions and Practical Setup
Preclinical metabolic studies used diet-induced obese rodents with body composition measured by densitometry or imaging, alongside lipolysis readouts in isolated adipocytes. The important design point is that diet and strain background strongly influence the outcome, so a study without a matched control arm on the same diet is difficult to interpret.
AOD-9604 development timeline evidence
| Stage | Result | Interpretation |
|---|---|---|
| Design rationale | Separate lipolysis from growth effects | Sound and well defined |
| Preclinical metabolic models | Reported fat mass changes | Diet and strain dependent |
| Human efficacy trials | No clinically meaningful weight loss | Decisive negative |
| Development status | Discontinued | Material fact, not a footnote |
Practical Notes for the Bench
- Check whether clinical development was completed before citing efficacy.
- Separate receptor-mediated growth effects from lipolytic claims.
- Treat discontinued development as a material fact, not a footnote.
Frequently Asked Questions
Did AOD-9604 work in humans?
No. Clinical trials did not demonstrate meaningful weight-loss efficacy and development was discontinued.
What was the design goal?
To retain the lipolytic activity associated with growth hormone while avoiding receptor-mediated growth-promoting effects.
Why is it still available?
It persists in research catalogues despite discontinued development, which is common for compounds with name recognition.
Is a discontinued compound still useful to study?
Yes, as a case study. The value lies in understanding why a sound mechanistic rationale failed at the clinical stage, which is a generalisable lesson.
Related Reading
- thymosin alpha-1
- TB-500 thymosin beta-4
- delta sleep-inducing peptide
- solid-phase peptide synthesis
- peptide cleavage deprotection
References & Further Reading
- Wilding J et al. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004. PubMed 15134286
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Dr. Marcus Feld, Molecular Pharmacology, In Vitro Models.